Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025. Investors interested in serving as lead plaintiff must file a motion with the court by April 6, 2026. Those who purchased shares during this period may be eligible for compensation through a contingency fee arrangement, meaning no upfront costs.
To participate in the class action, investors can submit their information online or contact Phillip Kim, Esq. via phone or email for more details.
**Why this matters:**
This lawsuit offers Ultragenyx investors an opportunity to seek potential compensation related to their stock purchases during the specified timeframe. Acting before the April 6 deadline is essential for those wishing to take a more active role in the litigation process.
Source: NewsData